Dr n. med. Mateusz Bilski/ Radioterapeuta onkologiczny/ Radioonkolog

10/08/2025

🌍 A Month of Learning, Growth, and Inspiration in Milan 🇮🇹
I have just completed a one-month clinical and research fellowship at the Department of Radiotherapy, European Institute of Oncology (IEO) in Milan — an institution renowned for its excellence in patient care, innovation, and research.
This experience was a unique opportunity to refine my skills in state-of-the-art stereotactic radiotherapy (SBRT,SRS), proton therapy, and brachytherapy (interventional radiotherapy), as well as to engage in extensive scientific work, contributing to ongoing research projects and exchanging knowledge with leading experts.
The team’s work is characterized by a rare combination of precision, passion, and continuous curiosity — they constantly expand their knowledge, meticulously analyze clinical outcomes, and set trends that shape oncology practice in Europe and beyond.
I am especially grateful to Prof. Barbara Jereczek-Fossa, Head of the Department of Radiotherapy, for her warm welcome and for making this fellowship such an inspiring journey. My sincere thanks also go to Dr. Stefano Durante for his guidance and mentorship during my stay, and to Dr. Andrea Vavassori, Head of Brachytherapy — a true artist in his field, whose expertise and dedication to patient care are second to none.
My heartfelt thanks extend as well to the entire radiotherapy team — too many outstanding individuals to name here — for their openness, generosity, and willingness to share their experience.
This fellowship was made possible thanks to the Jakubs' hr. Potocki Foundation research grant, for which I am profoundly thankful. Their support allowed me to experience firsthand the collaborative spirit and cutting-edge techniques of one of Europe’s leading radiation oncology centers.
What I bring back with me is not only advanced technical expertise and scientific knowledge, but also the inspiration drawn from an extraordinary group of people whose enthusiasm for research and commitment to their patients are truly contagious.
Grazie, Milano — until next time! 🇮🇹✨

31/07/2025

Dear Colleagues,

Another successful edition of the Contouring Workshop in Prostate Cancer Radiotherapy is behind us!

This time, the workshop took place on May 30–31, 2025, in Warsaw.

Together with the Scientific Committee, including:

Prof. Jacek Fijuth, MD, PhD
Łukasz Kuncman, MD, PhD
Mateusz Bilski, MD, PhD
Mateusz Dąbkowski, MD, PhD
Maja Lisik-Habib, MD, PhD
we delivered an up-to-date, case-based review of contouring guidelines and radiotherapy volumes for nearly 25 radiation oncologists across various clinical scenarios in prostate cancer.

I had the pleasure of presenting key principles for defining target volumes in:

Primary prostate cancer
Post-prostatectomy radiotherapy
Elective and involved nodal irradiation, including pelvic lymph nodes and common iliac involvement (N1/M1a disease)
On the second day, we conducted interactive hands-on workshops, where we worked through real clinical cases and exercised precise volume delineation techniques alongside our participants.

The program also featured lectures on pelvic radiological anatomy, interpretation of MRI findings in prostate cancer, and tips on how to read detailed radiological reports from genitourinary radiologists.

These workshops continue to be an invaluable platform for knowledge exchange and refinement of skills—ensuring that we all stay up-to-date with the latest evidence, guidelines, and innovations to deliver optimal, personalized care to our patients.

Heartfelt congratulations to all the participants and the organizing team—and thank you once again for the invitation and trust.

Let’s keep pushing the boundaries of excellence in prostate cancer radiotherapy together!

19/07/2025

📚 Medycyna oparta na dowodach to nie tylko hasło. To codzienna odpowiedzialność, która zaczyna się od odwagi, by z pokorą analizować własne wyniki.

📌 Why Analyzing Our Own Treatment Outcomes Matters

Recently, I had a fascinating conversation with one of my patients — one that, I believe, reflects the growing awareness among patients and a question more and more responsible physicians are beginning to ask.
He asked:
“Doctor, nowadays many centers showcase new technologies or treatment tools on social media — which is helpful, of course — but why does no one seem to talk about their actual treatment outcomes? How do they know what works if they don’t analyze their results?”

This question hits the mark.

🎯 The most reputable oncology centers don’t just rely on technologies — they constantly analyze the outcomes of their own work.
They conduct both prospective and retrospective studies, learning from real-life patient data rather than assumptions or intuition.
These insights help improve effectiveness, minimize adverse effects, and refine treatment strategies — not based on belief, but on measurable outcomes.

It is not enough to believe that we're helping. We must demonstrate it and improve upon it — ideally through peer-reviewed publications, verified by experts in the field.

📊 This is why we are proud to present the latest results from our team.

We now share our third clinical cohort of patients with colore**al liver metastases — this time in the context of induced oligoprogression, i.e., patients initially presenting with widespread metastatic disease who, following systemic therapy, developed progression limited to a small number of liver lesions.
Our focus: the role of CT-guided HDR brachytherapy in this scenario.

📌 Study Summary:

In the largest reported cohort to date, we evaluated CT-guided high-dose-rate brachytherapy (CT-BRT) in patients with colore**al cancer liver metastases undergoing induced oligoprogression (n=75).
Median OS was 17 months, median PFS 10 months, with minimal toxicity (1% Grade 3, none above G3).
Treatment responses included: CR in 8%, PR in 31%, SD in 47%, and PD in 15%.
OS was positively influenced by achieving disease control with a high dose. PFS was affected by the number of metastases and presence of extrahepatic disease (notably abdominal/pelvic lymph nodes).

📎 Manuscript: Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colore**al cancer liver metastases
👉 Full publication https://www.nature.com/articles/s41598-025-09227-0
— we invite feedback from colleagues and patients alike!

🧠 Final Thought:
📚 Evidence-based medicine is not just a slogan. It is a daily responsibility — and it begins with the humility to analyze our own results.

**alCancer

04/07/2025

🎯 Mission Possible: Precision and Personalization in Oncology
🗓️ Warsaw, May 16–17, 2025

Dear Colleagues,

I had the honor of being invited as a speaker at this year's "Mission Possible – Precision and Personalization in Oncology" conference in Warsaw.

During my lecture, I presented the latest clinical data on salvage radiotherapy for prostate cancer recurrence after prior curative radiotherapy. The talk was titled:

"The Role of Brachytherapy in Prostate Cancer Recurrence After Definitive Radiotherapy – Clinical Experience and Recent Evidence"

We discussed three recent meta-analyses comparing salvage modalities – stereotactic radiotherapy (SBRT), high-dose-rate brachytherapy (HDR-BT), and low-dose-rate brachytherapy (LDR-BT):

📊 5-year recurrence-free survival (RFS) & median RFS:

SBRT: 40.6% (95% CI: 34.4–46.7%), median: 36.2 months
HDR-BT: 52.3% (95% CI: 47.5–57.4%), median: 61.2 months
LDR-BT: 63.5% (95% CI: 59–68.7%), median: 131.6 months

We also had the opportunity to present our own clinical results from Lublin – 5-year RFS of 68% after slavage HDR brachytherapy, confirming that our team is delivering excellent outcomes for patients.

With growing evidence supporting LDR brachytherapy in this setting, we’re thrilled that our center in Lublin now offers LDR treatment as of six months ago — further enhancing the personalized care options available to our patients with recurrent prostate cancer.

🙏 I would like to express my sincere thanks to the Scientific and Organizing Committee, especially Prof. Jacek Fijuth and Prof. Łukasz Kuncman, for the kind invitation and for organizing such an outstanding academic event.

https://www.cmeducation.pl/event/radioterapia/precyzja-i-personalizacja

27/06/2025

🧠 Gliomas remain among the most complex and aggressive brain tumors we face in oncology.
After surgery, radiotherapy is a cornerstone of treatment, offering a critical chance to improve local control and patient outcomes. But in these cases, precise delineation of the target volume is not just a technical step — it’s a clinical responsibility. Postoperative anatomy, peritumoral edema, and evolving guidelines make this task time-consuming, highly specialized, and mentally taxing for radiation oncologists.

✨ What if we could reduce this burden — without compromising quality?

🚀 That’s exactly the motivation behind our latest work:
“Computer-aided target volume delineation for postoperative radiation therapy in brain glioma patients with the use of the hybrid artificial intelligence model”
📌 Now published in European Physical Journal – Special Topics
🔗 https://doi.org/10.1140/epjs/s11734-025-01688-8

In this preliminary study, we introduce HAICS (Hybrid Artificial Intelligence-based Contouring System) — a clinician-supportive AI tool that automates target volume contouring for glioma radiotherapy. By integrating machine learning, interactive algorithms, and syntactic pattern recognition, HAICS provides initial contours that oncologists can adjust and approve — saving time and freeing cognitive bandwidth for patient care and research.

🛠️ And here’s the heart of it:
We developed this with limited resources, but with unlimited passion — in collaboration with outstanding experts from Jagiellonian University. This project proves that with collaboration and commitment, innovation is possible even without vast infrastructure.

🌍 This is just the beginning. We hope HAICS inspires a future where AI becomes a tool for empowerment, not replacement — letting us focus more on patients, decisions, and science.

🙏 Huge thanks to all co-authors and contributors who believed in this idea and helped turn it into a published study.

26/06/2025

🌟 An unforgettable experience and a powerful source of inspiration!�
I am truly honored to have been chosen to participate in the European program Agora 2025: ESTRO Future Leaders Retreat – Shaping Radiotherapy Leadership for Tomorrow, Together.
Thank you, ESTRO, for choosing me as one of the participants from around the world based on my CV and personal reflections on the future of our field. This recognition is a tremendous honor and serves as a powerful motivation to keep learning, growing, and making impactful contributions to the future of radiation oncology.
🚀 Agora 2025 brought together passionate early-career professionals to:�
✅ Explore the evolving landscape and challenges in modern radiotherapy
✅ Collaborate on ESTRO’s long-term vision and strategic direction�
✅ Build lasting connections with peers and ESTRO leadership�
✅ Be recognised as part of a new generation of leaders shaping the future of our field
Together with colleagues from all over the world, we had the chance to reflect, discuss, and co-create ideas to shape the future of radiotherapy.
🙏 I am sincerely grateful to all the mentors, previous and current ESTRO Presidents, faculty, and organisers for their incredible work and dedication — from the pre-meeting webinars to the main retreat. Your support and energy were invaluable.� And to all fellow participants — thank you! With your vision and commitment, the future of ESTRO and radiation oncology is truly in excellent hands.
Let’s keep the momentum going! 💡🌍

17/06/2025

🎉 Congratulations to our Polish–Italian–German–American team!
Once again, we’ve shown that cross-border collaboration, scientific dedication, and a shared commitment to improving patient care can lead to meaningful advances in oncology 💪🌍
🧠 Our latest publication, titled:
“Interventional stereotactic radiotherapy (brachytherapy) for unresected brain metastases: A systematic review of outcomes and toxicity”
has just been published in Critical Reviews in Oncology and Hematology.
This work represents the most comprehensive synthesis to date of available evidence on stereotactic brachytherapy (SBT) — a form of interventional radiotherapy — used in the treatment of intact (unresected) brain metastases.
Despite its precision and promising efficacy, SBT remains underutilized in clinical practice. With this study, we aim to highlight its relevance and future potential.
🔍 Key takeaways from our systematic review:
✔️ Excellent local control (LC):
1-year LC rates ranged from 93.3% to 100%, even in challenging clinical scenarios such as large or radio-recurrent brain metastases.
✔️ Survival outcomes:
Median overall survival (OS) reached up to 28.4 months, with RPA class I patients consistently achieving the best prognoses.
✔️ Low toxicity and safety profile:
Across all studies, no grade 3/4 acute toxicities were reported. Postoperative morbidity within 30 days was low (0%–6.6%) and there were no fatal complications.
✔️ Consistent methodology:
All studies utilized Iodine-125 (I-125) seeds. Temporary implantation was most common, while permanent implants allowed for higher total doses (up to 150 Gy) and longer treatment durations.
🧠 Why does this matter?
SBT offers a minimally invasive, highly targeted, and safe approach to managing unresected brain metastases — especially for patients who may not be surgical candidates or who have received prior radiotherapy.
Yet, implementing this method is not trivial. It requires seamless, multidisciplinary coordination between radiation oncologists, neurosurgeons, physicists, and oncology nursing teams.
💡 Let’s rise to this challenge and create more specialized, high-performance centers where interventional radiotherapy becomes a standard option — not an exception — in the treatment of brain metastases. Our patients deserve access to the best that modern oncology can offer.
📖 Read the full open-access article here:
👉 https://www.sciencedirect.com/science/article/pii/S1040842825001659?via=ihub

07/06/2025

This year’s ESTRO 2025 Congress — the flagship event of the European Society for Radiotherapy and Oncology — was, as always, an unforgettable experience! 🌟

Year after year, this meeting grows in both scale and impact, bringing together more participants, more abstracts, and above all — an incredible amount of cutting-edge knowledge and inspiring connections that fuel both scientific and clinical growth. Every time, it inspires me more! 💡

The program is packed — scientific sessions run in parallel from early morning to late evening, offering insights across the entire field of radiation oncology.

🔬 This year, I had the opportunity to attend a pre-congress course titled:
"Multidisciplinary management of bladder cancer: how to implement contemporary radiotherapy in your department?" — where I exchanged perspectives with European experts on the central role of radiotherapy, alongside surgery, in bladder cancer care.

🎤 I was also honored to co-chair, together with Primoz Petric from Switzerland, the symposium:
“Brachytherapy for cancer re-irradiation: The best tool in the shed?” — presenting the latest advances and evidence in the use of interventional radiotherapy (brachytherapy) for re-irradiation.

📢 This year we presented six abstracts, including two selected among the top 5% of all submissions — huge thanks and congratulations to the international teams I had the privilege of working with!

Even more exciting is that both top-rated abstracts focused on my favorite topics: brachytherapy and stereotactic radiotherapy:

1️⃣ Target volume definition and organ at risk delineation in HDR brachytherapy for re**al cancer – consensus-based GEC-ESTRO guidelines
2️⃣ Outcomes of SBRT for PSMA PET diagnosed hormone-sensitive oligorecurrent prostate cancer: results from a large international multi-center cohort

🧠 We also shared three studies on liver metastasis brachytherapy, including one in collaboration with our colleagues from the University of Bonn:

3️⃣ Interventional radiotherapy (I-RT) for liver oligometastatic disease from colore**al cancer – a single institution retrospective analysis
4️⃣ Acute and late toxicity profile of liver interventional radiotherapy after direct (non-Seldinger) application – a single institution analysis
5️⃣ A dosimetric comparison of different radiotherapy modalities for non-resected liver metastases

Lastly, we presented the results of our international collaborative team developing a new prognostic tool for stratifying patients with oligorecurrent prostate cancer, enabling metastasis-directed SBRT alone while delaying systemic therapy:

6️⃣ Development and internal validation of a nomogram predicting ADT-free survival in oligorecurrent prostate cancer treated with metastasis-directed SBRT

It’s been an intense, inspiring, and deeply energizing experience — and once again, ESTRO delivers tons of motivation for what’s next! 🚀

31/05/2025

The analysis of our second cohort- this time patients with induced oligopersistence of colore**al cancer liver metastases and treated with brachytherapy (interventional radiotherapy) was published this month in the Clinical and Experimental Metastasis Journal.

Congratulations to the entire team for their tireless effort! :)

„EORTC/ESTRO defined induced oligopersistence of liver metastases from colore**al cancer - outcomes and toxicity profile of computer tomography-guided high-dose-rate brachytherapy.”

Colore**al cancer (CRC) often leads to liver metastases, which may be resistant to systemic therapy. This study assessed the outcomes and toxicity of computed tomography (CT)- guided high-dose-rate (HDR) brachytherapy (BRT) in oligopersistent liver metastases from colore**al cancer (CRC).
The study included patients with liver metastases classified as EORTC/ESTRO-defined induced oligopersistence after multiple systemic therapy lines. Up to four persistent liver metastases per patient were treated with CT-guided brachytherapy (CT-BRT). Treatment response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). The analysis focused on overall survival (OS), progression-free survival (PFS), tumor burden score (TBS), and the prognostic value of changes in metastasis size.
Sixty-eight CRC patients were enrolled. During a median follow-up of 17 months, the median overall survival (OS) was 16 months, and the median progression-free survival (PFS) was 13 months.
Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were observed in 7%, 35%, 44%, and 6% of patients, respectively. Patients with an objective response (ORR) of 42% had longer overall survival (OS) and progression-free survival (PFS) than those without it. OS was affected by lymph node metastases and reduction in metastasis size, while the administered dose also influenced PFS.
Multivariate analysis revealed that overall survival (OS) was associated with lymph node metastases (p = 0.001) and overall response rate (ORR) (p = 0.004). At the same time, PFS was linked to the difference in tumor burden score (TBS) (p = 0.017) and the size of the single metastasis after post-CT-BRT (p = 0.026).
CT-BRT for CRC oligopersistent liver metastases is effective, improving PFS and OS, with TBS difference identified as a key response parameter for future strategies.

https://link.springer.com/article/10.1007/s10585-025-10348-z

Colore**al cancer (CRC) often leads to liver metastases, which may be resistant to systemic therapy. This study assessed outcomes and toxicity of computed tomography (CT) guided high-dose-rate (HDR) brachytherapy (BRT) in oligopersistent liver metastases from CRC. The study included patients with li...

21/05/2025

Szanowni Państwo,

W dniach 04-05.04.2025 r. W Lublinie odbyła się konferencja SPRING EXCELLENCE LUNG CANCER, THORACIC TUMOURS, AND GYNECOLOGICAL CENTERS SCHOOL.

Kongres umożliwił wymianę doświadczeń wśród specjalistów m.in. onkologii, radioterapii, ginekologii i położnictwa, patomorfologii łącząc zagadnienia dotyczące terapii nowotworów płuca oraz nowotworów ginekologicznych.

Dziękuje komitetowi organizacyjnemu za zaproszenie do wygłoszenia dwóch wykładów tym razem o tematyce ginekologicznej:

Miejsca radioterapii w leczeniu raka endometrium.

Miejsca radioterapii w leczeniu raka szyjki macicy.

Radioterapia/radiochemioterapia + brachyterapia (radioterapia interwencyjna) w nowotworach szyjki macicy stanowi główną metodę terapeutyczną.

Według odświeżonych rekomendacji ESGO/ESTRO/ESP z 2023 roku ma ona najszersze zastosowanie i ma swój udział na każdym etapie leczenia. Dotyczy to również tzw. choroby oligometastatycznej (tzn. z niewielką ilością przerzutów gdzie wykorzystuje się dodatkowo radioterapię stereotaktyczna (SBRT/SRS), brachyterapię (radioterapię interwencyjną), jak również w sytuacji nawrotów po radioterapii (do tzw. reiradiacji głównie za pomocą brachyterapii (radioterapii interwencyjnej), radioterapii stereotaktycznej (SBRT/SRS).

Ogromnego znaczenia nabrała również diagnostyka nowej generacji w postaci badania PET/CT, które jest rekomendowane już od stopnia zaawansowania IB3 lub niższego w przypadku podejrzanego obrazu węzłów chłonnych w badaniach MRI/CT.

Aktualne rekomendacje ESGO/ESTRO/ESP z 2025 r. dotyczące raka trzonu macicy (zaprezentowane na tegorocznym kongresie ESGO) rekomendują radioterapię uzupełniającą według uaktualnionego podziału na grupy ryzyka.
Podstawowe znaczenie ma odpowiednia diagnostyka i charakterystyka molekularna tych nowotworów (absolutnie niezbędna do osiągnięcia optymalnych wyników terapii).

U pacjentek z rakiem trzonu macicy radioterapia jest rownież coraz szerzej rekomendowana w przypadku rozpoznania choroby oligometastatycznej oraz w terapii ew. nawrotów po radioterapii (reiradiacji) jak również u pacjentek niekwalifikujących się do zabiegu operacyjnego (tutaj również radioterapia to terapia radykalna z bardzo dobrymi wynikami).

Jedno jest pewne radioterapia w nowotworach ginekologicznych przeżywa rozkwit.
Nowoczesne techniki napromieniania/ adaptacyjna brachyterapia sterowana obrazem (IGABT)/ radioterapia stereotaktyczna (SBRT/SRS) umożliwiają optymalizację i poprawę rokowania również u pacjentek z wyższym zaawansowaniem choroby, chorobą przerzutową czy w przypadku nawrotów.

Gratulacje dla organizatorów oraz wszystkich wykładowców.

11/05/2025

Congratulations to the entire team!

Our recent study, made possible through our Polish-German collaboration, involved working alongside colleagues from the Institute of Experimental Oncology and the Radiotherapy Department in Bonn. We compared different radiotherapy modalities: high dose-rate (HDR) brachytherapy, electronic brachytherapy (eBT), and stereotactic body radiotherapy (SBRT) for the treatment of liver metastases.

The role of radiotherapy in addressing limited liver metastases is evolving quickly, with various technical approaches now available. In this multicentric study, we included 30 patients who had been treated for solitary liver metastases. We planned and dosimetrically compared interstitial HDR brachytherapy, stereotactic body radiation therapy (SBRT), and kilovoltage electronic brachytherapy (eBT) using a single dwelling point. Each modality was administered in a single fraction of 25 Gy.

The primary endpoint of our study was to assess the difference in exposure to healthy liver tissue. Secondary endpoints included target volume coverage, radiation dose to surrounding organs at risk (OARs), and treatment time.

Results:
The median lesion volume was 9.3 cm³, with a range from 2.5 to 29.7 cm³. We found that electronic brachytherapy provided significantly better sparing of OAR doses compared to SBRT. The radiation exposure to healthy liver tissue was significantly lower with eBT and HDR compared to SBRT. However, the coverage for clinical target volume (CTV) D90% and D95% was superior for SBRT compared to both HDR and eBT.

Conclusion:
Minimally invasive single-catheter electronic brachytherapy (eBT) offers a promising new approach for treating unresectable liver metastases, achieving optimal sparing of OAR doses, though with suboptimal target volume coverage. To combine the benefits of both approaches, a multi-dwelling eBT technique, similar to HDR, may improve clinical applicability by optimizing target coverage while maintaining excellent doses to OARs. Future prospective studies are necessary to further define its role among established liver-directed therapies.

https://www.ctro.science/article/S2405-6308(25)00037-0/fulltext

Liver metastases develop in up to 5 % of cancer patients and generally carry a poor prognosis, with a 1-year survival rate of approximately 15 % [1]. Over the past decades, metastasis-directed treatment has improved substantially, with different locoregional modalities becoming more widely availab...

01/05/2025

Szanowni Państwo,

Rak płuca rozpoznawany jest w Polsce u około 20-22000 pacjentów rocznie. Niestety liczba ta stale rośnie.

Jedną z zasadniczych metod leczenia tego nowotworu jest radioterapia.

W zależności od rodzaju nowotworu płuca, jego zaawansowania i biologii radioterapię stosuje się jako metodę: samodzielną, w połączeniu z chemioterapią +/- immunoterapią/inihibitorami kinazy tyrozynowej, przedoperacyjnie lub pooperacyjnie.

Standard postępowania stale ewoluuje o czym świadczą np. uaktualniane kilka/kilkanaście razy w roku zalecenia NCCN (National Comprehensive Cancer Network).

Jako radionkolodzy, nieustannie uaktualniamy swoją wiedzę w ujęciu interdyscyplinarnym, jak również biorąc pod uwagę Nasz warsztat radioonkologiczny.

W dniach 21-22.03.25 r. w Warszawie przeprowadziliśmy warsztaty z konturowania (wyznaczania obszaru/ów poddawanych radioterapii) w raku płuca dla lekarzy radionkologów z całej Polski.

Prowadzenie takich warsztatów to zawsze doskonała okazja do odświeżenia/zaktualizowania swojej wiedzy zarówno dla uczestników jak i wykładowców.

Staramy się poruszyć/przekazać treść najnowszych międzynarodowych rekomendacji, przedyskutować elementy, które nie są jednoznacznie sformułowane i wskazać kierunki rozwoju/trendy rozwoju radioterapii.

Dziękuję komitetowi naukowemu
Szanownemu Panu Prof. dr hab. n.med. Jackowi Fijuthowi oraz
dr hab. n.med. Łukaszowi Kuncmanowi za zaproszenie do grona prelegentów.

Tym razem zaprezentowałem dwa wykłady pt.:

Konturowanie w niedrobnokomórkowym raku płuca

Konturowanie w drobnokomórkowym raku płuca. Kiedy naciek naczyń jest przeciwskazaniem do radioterapii?

Po sesji typowo wykładowej odbyły się warsztaty, na których mieliśmy okazję przećwiczyć i zaktualizować swoje umiejętności.

Gratulacje dla uczestników, organizatorów oraz wszystkich prelegentów.

https://cmeducation.pl/event/radioterapia/konturowanie